Clinical Cerenkov luminescence imaging of (18)F-FDG.
The aim of this study was to determine the feasibility of Cerenkov luminescence (CL) imaging of patients undergoing diagnostic (18)F-FDG scans to detect nodal disease.


METHODS
Patients undergoing routine (18)F-FDG PET/CT for various malignancies consented to being scanned for CL. White-light and Cerenkov images (5-min acquisition) of the surface of the patient contralateral to and at the site of nodal (18)F-FDG uptake were acquired using a cooled, intensified charge-coupled-device camera.


RESULTS
The camera demonstrated linear correlation between activity and counts into the low nanocurie range using (18)F-FDG. Imaging of patients revealed the presence of (18)F-FDG uptake in nodes that demonstrated uptake on PET. A correlation between maximum standardized uptake value from PET and counting rate per area on the CL imaging was established.


CONCLUSIONS
CL imaging with diagnostic doses of (18)F-FDG is feasible and can aid in detecting disease in the clinical setting.
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and.
Daniel L J
DL
Thorek
Christopher C
CC
Riedl
Jan
J
Grimm
D015331:Cohort Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D049449:Luminescence; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D061848:Optical Imaging / Q000379:methods*; D017785:Photons; D010865:Pilot Projects; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
18F-FDG; Cerenkov luminescence imaging; PET/CT; clinical